Intradialytic hypotension is a most frequent complication of hemodialysis and may contribute to cardiovascular events and high mortality. There is a hypothesis that an increase in adenosine generation during hemodialysis may cause vasodilation and a decrease in cardiac output, which results in systemic hypotension. We studied whether this can be blocked by an adenosine A1 receptor antagonist. We investigated the effects of an A1 antagonist, FK352, injection in 30 chronic hemodialysis patients with frequent intradialytic hypotension by a prospective, multicenter, double-blind placebo-controlled study for 4 weeks after 4 weeks of the observation period. Intradialytic hypotension was defined as systolic blood pressure (SBP) less than 110 mmHg, with SBP drop of more than 30 mmHg from the predialysis level. The efficacy of FK352 was primarily assessed by the reduction rate of dialysis hypotension between the FK352 and placebo groups. Incidence of emergency treatments caused by hypotension was evaluated. FK352 (50 mg, intravenous) or an equivalent placebo was injected into the dialysis circuit 1 h after starting dialysis. Blood pressure and heart rate were monitored every 30 min during dialysis. FK352 significantly improved intradialytic hypotension (P ¼ 0.046), in that the reduction rates of intradialytic hypotension in the FK352 and placebo groups were À12.8% (Q1 (first quantile), Q3 (third quantile): À27.5, À1.7), and þ 8.3% (Q1, Q3: À16.6, þ 16.7), respectively. The frequency of discontinuation of dialysis was significantly reduced by FK352. No apparent side effects were observed from treatment with FK352. In conclusion, the A1 antagonist FK352 may offer a novel therapeutic option for chronic dialysis patients associated with intradialytic hypotension.
Intradialytic hypotension is a most frequent complication of hemodialysis and may contribute to cardiovascular events and high mortality. There is a hypothesis that an increase in adenosine generation during hemodialysis may cause vasodilation and a decrease in cardiac output, which results in systemic hypotension. We studied whether this can be blocked by an adenosine A1 receptor antagonist. We investigated the effects of an A1 antagonist, FK352, injection in 30 chronic hemodialysis patients with frequent intradialytic hypotension by a prospective, multicenter, double-blind placebo-controlled study for 4 weeks after 4 weeks of the observation period. Intradialytic hypotension was defined as systolic blood pressure (SBP) less than 110 mmHg, with SBP drop of more than 30 mmHg from the predialysis level. The efficacy of FK352 was primarily assessed by the reduction rate of dialysis hypotension between the FK352 and placebo groups. Incidence of emergency treatments caused by hypotension was evaluated. FK352 (50 mg, intravenous) or an equivalent placebo was injected into the dialysis circuit 1 h after starting dialysis. Blood pressure and heart rate were monitored every 30 min during dialysis. FK352 significantly improved intradialytic hypotension (P ¼ 0.046), in that the reduction rates of intradialytic hypotension in the FK352 and placebo groups were À12.8% (Q1 (first quantile), Q3 (third quantile): À27.5, À1.7), and þ 8.3% (Q1, Q3: À16.6, þ 16.7), respectively. The frequency of discontinuation of dialysis was significantly reduced by FK352. No apparent side effects were observed from treatment with FK352. In conclusion, the A1 antagonist FK352 may offer a novel therapeutic option for chronic dialysis patients associated with intradialytic hypotension. End-stage renal disease (ESRD) patients are continuously increasing and the total number of hemodialysis patients is estimated to be over 1 650 000 in the world. 1 In Japan, the number of ESRD patients in 2004 exceeded 240 000, and the patients receiving long-term hemodialysis has considerably increased. More than 15 000 hemodialysis patients have been undergoing hemodialysis therapy for more than 20 years. Long-term dialysis therapy causes various complications including intradialytic hypotension.
There are two types of dialysis hypotension: intradialytic hypotension and chronic persistent hypotension. Up to 33% of hemodialysis patients are suffering from intradialytic hypotension, which requires an action to resume blood pressure during hemodialysis, 2,3 and the incidence of intradialytic hypotension is expected to increase in accordance with the increase of the elderly, diabetic patients, and patients with cardiovascular diseases. 4 Intradialytic hypotension often engenders hemodialysis interruption and may be responsible for a reluctance in patients to extend their dialysis treatment time, eventually leading to increased morbidity and mortality by brain ischemia and cardiovascular diseases. 5, 6 Several factors contribute to intradialytic hypotension. These include rapid fluid removal, rapid reduction in plasma osmolality, autonomic dysfunction, limited cardiac reserve, and increased synthesis of endogenous vasodilators. 7, 8 The gradual blood pressure reduction results from an intravascular hypovolemic condition due to hemodialysis. In contrast, sudden and profound hypotension from diminished cardiac output and vasodilation has been theorized. Krepel et al. 9, 10 reported that the level of relative blood volume was not correlated with blood pressure and the level of relative blood volume reduction at which hypotension occurred was highly variable. The accumulation of the locally released adenosine may play a central role in sudden intradialytic hypotension. The proposed hypothesis is that a vicious cycle may occur in patients with sudden hypotension: hypotension induces ischemia, which, in turn, increases local adenosine release, which then causes inhibition of norepinephrine release and eventually causes vasodilation, thus resulting in deepening hypotension. 11, 12 In fact, concentrations of adenosine and its metabolite, inosine, and hypoxanthine, are reported to increase after hemodialysis.
Adenosine exerts its physiological actions to stimulate adenosine receptors (A1, A2a, A2b, and A3) on the cell membrane. 13 Functions of A1 and A2a receptors have been well studied. Adenosine A1 receptor stimulation results in suppression of cardiac contractility, heart rate reduction, suppression of catecholamine release from sympathetic nerve endings, and renin release. FK352, an adenosine receptor A1 antagonist, exhibits high affinity and high selectivity for the human adenosine A1 receptor. Although the central nervous system abounds in adenosine A1 receptors, 14 FK352 has little effect on the central nervous system. One of the reasons is thought to be that the character of hydrophilicity of FK352 does not allow it to be distributed into the central nervous system (data not shown).
To prove the hypothesis that dialysis hypotension is caused by ischemia-induced adenosine generation, we investigated the effects of FK352 infusion on dialysis hypotension by a multicenter, randomized, double-blind, placebo-controlled, intergroup comparative study.
RESULTS
Effects of FK352 treatment on the incidence of intradialytic hypotension FK352 significantly improved intradialytic hypotension (P ¼ 0.046), in that the reduction rates of dialysis hypotension in the FK352 and placebo groups were À12.8% (Q1 (first quantile), Q3 (third quantile): À27.5, À1.7), and þ 8.3% (Q1, Q3: À16.6, þ 16.7), respectively ( Figure 1b) . Intradialytic hypotension was significantly suppressed in the FK352 group (P ¼ 0.010), whereas it was not changed in the placebo group (P ¼ 0.637) ( Figure 1a) .
As the two variables of frequency of intradialytic hypotension and duration of hemodialysis exhibited imbalance (Po0.15), the incidence of intradialytic hypotension during the observation period was adjusted. After adjustment, FK352 significantly suppressed intradialytic hypotension also (P ¼ 0.030).
To further analyze the efficacy of FK352 on intradialytic hypotension, we compared the FK352 and placebo groups after omitting the dialysis sessions in which body fluid was removed at the excessive ultrafiltration rate of more than 0.3 ml/kg/min. Three patients in the FK352 group were omitted because they were frequently treated with the excessive ultrafiltration rate. On the other hand, no patient in the placebo group was removed from the data for analysis. The reduction rates of dialysis hypotension in the FK352 and placebo groups were À12.8% (Q1, Q3: À30.0, À8.3) and þ 8.3% (Q1, Q3: À16.6, þ 16.7), respectively (Figure 2 ), suggesting that FK352 significantly improved intradialytic hypotension (P ¼ 0.049).
As shown in Figures 3 and 4 , the intradialytic hypotension of the hemodialysis patients was significantly suppressed by FK352 and the efficacy was more prominent in proportion to the degree of drop in blood pressure. With the intradialytic hypotension defined at systolic blood pressure (SBP) less than 100 mmHg, the reduction rates of dialysis hypotension in the FK352 and placebo groups were À16.7% (Q1, Q3: À34.5, þ 0.8) and þ 8.3% (Q1, Q3: À16.7, þ 25.0), respectively ( Figure 3 ), suggesting that FK352 significantly improved intradialytic hypotension (P ¼ 0.018). With intradialytic hypotension defined as SBP less than 90 mmHg, the reduction rates of dialysis hypotension in the FK352 and placebo groups were À12.5% (Q1, Q3: À16.7, 0.0) and þ 2.8% (Q1, Q3: 0.0, þ 27.3), respectively ( Figure 4 ), suggesting that FK352 significantly improved intradialytic hypotension (P ¼ 0.032). FK352 prominently improved intradialytic hypotension, particularly in severer cases.
Effect of FK352 on events with emergent treatment during hemodialysis
The incidence of dialysis sessions with emergency treatments is shown in Table 1 . The incidence of infusion was not different between the FK352 and placebo groups during the observation period (Table 1 ). However, discontinuation of dialysis was significantly suppressed by FK352 treatment (Table 1 and Figure 5 ). The major problem of intradialytic hypotension is discontinued dialysis, which often causes overhydration and underdialysis of the patients. In the placebo group, only one of eight showed an improved change, whereas all the subjects in the FK352 group ( Figure 5 ) had reductions in the frequency of discontinuation or suspension of fluid removal.
Pharmacokinetics of FK352 in dialysis patients
Plasma concentration of FK352 in hemodialysis patients was initially at 10 mg/ml and gradually decreased to 1 mg/ml, 2 h after the injection ( Figure 6 ). The plasma concentrations of FK352 of hemodialysis patients were similar to those of healthy volunteers. No apparent side effects were observed with use of FK352 for dialysis hypotension.
DISCUSSION
It is critically important to keep an adequate dialysis dose and sufficient dialysis time for improving the prognosis of dialysis patients. Intradialytic hypotension is a major problem in maintaining adequate dialysis because it compels a limit to dialysis time and dialysis condition. In the present study, FK352 improved intradialytic hypotension significantly in chronic hemodialysis patients, who were intradialytic hypotension prone. Although the incidence of saline infusion for intradialytic hypotension was not significantly different with FK352 administration, the incidence of discontinuation of hemodialysis was significantly decreased, indicating that FK352 improves intradialytic hypotension, particularly in severer cases.
Intradialytic hypotension occurs as a result of intravascular hypovolemia and impaired cardiovascular reactivity to the decrease of intravascular volume. When the dry weight is optimal, the ultrafiltration rate is the main determinant of intravascular volume. The excess removal of extracellular volume, when the ultrafiltration rate is beyond 0.3 ml/kg/ min, frequently results in intradialytic hypotension. If the dialysis sessions with excess ultrafiltration beyond 0.3 ml/kg/ min are removed, the impact of FK352 on intradialytic hypotension becomes more prominent, as shown in Figures  2-4 . Most cases of intradialytic hypotension seem to happen by impaired cardiovascular reactivity. The mechanism for the impaired reactivity of the cardiovascular system is largely obscure although several hypotheses have been proposed: autonomic dysfunction, generation of adenosine and so on. It has been proven that the increase in adenosine, which is generated from ischemic tissue by ATP degradation, reduces vessel tone and lowers blood pressure. A high concentration of adenosine and its metabolites has been reported after ischemic events. Woolliscroft and Fox 15 demonstrated that the increase in urine oxypurine/creatinine ratio was observed after hypotensive events of 19 patients who were associated with chronic heart failure, liver diseases and so on. In hemodialysis patients under acetate dialysis, dialysis hypotension was often seen and plasma inosine, hypoxanthine, xanthine, and uric acid were increased after dialysis. 16 According to their data, the increase in ATP metabolites was prominent in acetate dialysis within 1 h after dialysis, which was often associated with dialysis hypotension, whereas bicarbonate dialysis was not often associated with a significant increase in ATP metabolites, although a mild peak was seen at 2 h after dialysis. The most relevant report was published by Shinzato et al. 11 They measured inosine, hypoxanthine and xanthine at the time of sudden hypotension and showed a significant increase in these adenosine metabolites at the time of hypotension. Guieu et al.
12 also measured serum adenosine and inosine concentrations in dialysis patients and showed that the serum adenosine concentrations were increased more than twice as much as the controls before and after dialysis.
A1 receptor inhibition was attempted by administration of caffeine in patients with hemodialytic hypotension. Shinzato et al. 11 showed that administration of caffeine attenuated dialysis hypotension significantly. These results suggest that adenosine may play a major role in dialysis hypotension. However, caffeine is not a selective A1 antagonist and increases blood pressure and heart rates in most cases. In contrast, FK352 is a selective A1 antagonist and does not affect cardiovascular function and locomotor activity in the brain.
What is the mechanism for prevention of dialysis hypotension by FK352? The A1 receptors, which are reported to be distributed in the ends of sympathetic nerves, suppress the release of catecholamines from the ends of the nerves. 17 Adenosine selectively inhibits contractions of the rabbit portal vein evoked by adrenergic nerve stimulation via activation of an A1 receptor. 18 This means that adenosine could inhibit constriction of peripheral vessels via the A1 receptors in the ends of the nerves. FK352 may restore the adenosine-induced decline in constriction. It is known that adenosine decreases cardiac function and expands coronary arteries to protect the organ from ischemia-induced damage. The cardiac action of adenosine is depression of sinoarterial and arterioventricular node activity, leading to a reduced heart rate. However, heart rate was not changed significantly in the present study. We might have missed the reduction in heart rate because we did not continuously monitor heart rate and blood pressure. In dialysis patients, the increase in adenosine concentration in peripheral tissue presumably precedes the increase in adenosine in systemic circulation, as peripheral tissue ischemia occurs in advance of systemic hypotension. Alternatively, the A1 antagonist may directly affect autonomic regulation. This possibility needs to be studied. The A1 receptor does not involve dilation of coronary arteries. These arteries express adenosine A2 receptors, which mediate vasodilation. 19 Therefore, FK352 does not inhibit these protective actions of adenosine. This has been reported as a beneficial role of antagonism of the cardiodepressant effects of adenosine. 19, 20 The cardiodepressant actions of adenosine may protect our bodies against hemorrhage or angina. However, it is plausible that the depressant effect of adenosine induces sudden hypotension, which in turn causes serious injuries to the brain and heart. FK352 does inhibit the excessive suppressive action of adenosine on cardiac function.
In our study, the frequency of dialysis hypotension was attenuated by FK352, but not totally eliminated. This result may imply that the administration of FK352 might have been insufficient to prevent the intradialytic hypotension in some cases. The adequate treatment dose of FK352 and injection time to completely prevent dialysis hypotension need to be determined by further studies. Alternatively, the cause of hemodialytic hypotension is variable and A1 inhibition is not enough to prevent dialysis hypotension.
In this study, intradialytic hypotension tended to happen more frequently in control subjects during the dosing period compared to the observation period. The reason is obscure, but we speculated that the patients were stressed about obeying the protocol because the dialysis condition was not to be changed for 8 weeks. Such a tense condition might Dialyzed patients Healthy subjects Figure 6 | Pharmacokinetics of FK352. Plasma FK352 concentration in healthy subjects (-) and dialyzed patients (----) .
reduce the frequency of intradialytic hypotension during the first 4 weeks of the observation period. The dialysis conditions, in particular dry weight, are usually made through fine adjustment to retain the patients' physical condition appropriately. There was a possibility that the real dry weight might be changed in the last 4 weeks, although the cardiothoracic ratio and the size of inferior vena cava were not changed. Nevertheless, the incidence of intradialytic hypotension was significantly reduced with FK352, suggesting that FK352 may be effective even under adverse conditions and we may be underestimating the action.
In conclusion, FK352 was clinically useful for improvement of intradialytic hypotension in this small clinical trial, particularly in severe cases, which may improve the prognosis of hemodialysis patients. The outcome of this study suggests that intradialytic hypotension is, at least in part, caused by generation of adenosine during hemodialysis in peripheral tissue. In addition, FK352 significantly reduces the frequency of emergency treatment during dialysis therapy, which may decrease the practical labor of the dialysis staff. The favorable impact of FK352 needs to be confirmed in a large-scale clinical trial by enrolling severer cases.
MATERIALS AND METHODS Study subjects
Chronic hemodialytic patients who were suffering from frequent intradialytic hypotension lasting 6 months were recruited from hospitals and outpatient clinics in the Osaka area between January of 2002 and January of 2003. The inclusion criteria were outpatients on chronic hemodialysis three times a week in a supine position, whose predialytic SBP is 120 mmHg or more, and who have four or more dialysis sessions with intradialytic hypotensive episode(s) out of 12 hemodialysis sessions in 4 weeks. Ages range from over 20 to less than 75 years of age. The exclusion criteria were as follows: patients with serious hemodialysis-induced hypotension, by which it means that hemodialysis could not be completed without a pressure agent. Patients with any of the following complications were excluded: serious hypertension (SBP 200 mmHg or more and diastolic blood pressure 110 mmHg or more), serious hemorrhage disease (cerebral hemorrhage and ulcer accompanied by hemorrhage), serious cardiovascular diseases (myocardial infarction that occurred in the past 6 months, severe heart failure), and liver diseases, diabetic retinopathy in pre-proliferative stage or proliferative stage (although cases with stabilized bleeding by photocoagulation were enrolled), severe anemia requiring blood transfusion and having just started erythropoietin therapy.
Informed consent was obtained from 53 patients. Twenty patients were withdrawn from the clinical trial for the following reasons: seven patients did not meet the criteria of dialysis hypotension; five patients voluntarily withdrew; five patients needed to have their dry weight changed; one was admitted to a hospital; one had trouble with a shunt; one could not have his/her dialysis condition adjusted. Three patients were omitted from the data for analysis because the number of dialysis treatments for statistical analysis on these patients was insufficient.
The Investigational Product Allocation Director independently decided the eligibility of subjects under inclusion criteria and exclusion criteria and allocated them to FK352 and placebo groups at a 1:1 ratio. An observation period of 4 weeks was established before the initial administration of the investigational product, and the Investigational Product Allocation Director judged when to progress to the dosing period.
Fourteen subjects (10 men, four women) were assigned to the placebo group and 16 subjects (11 men, five women) were assigned to the FK352 group. Patient profiles at the entry of this study are shown in Table 2 . The subjects provided written, informed consent for the study and approval was obtained from both the Osaka Prefecture Medical Association research ethics committee and the individual hospital review boards. The study was carried out in accordance with the Declaration of Helsinki.
, which is an adenosine receptor A1 antagonist developed by Fujisawa Pharmaceutical Co., Ltd, exhibits high affinity and high selectivity for human adenosine receptor A1.
Study protocol
The study was performed in a randomized, double-blind, placebocontrolled and comparative manner. All subjects were adjusted to a hemodialysis condition for 2 weeks followed by the observation period for 4 weeks, and finally the subjects were treated with FK352 or placebo administration for 4 weeks. During the dosing period, 50 mg of FK352 or placebo was administrated 1 h after hemodialysis, as the elimination half-life of FK352 is 3 h.
The hemodialysis adjusted condition period was set to ensure constant hemodialysis conditions during the observation period (4 weeks) and the medication period (4 weeks), totaling 8 weeks. During this period, all hemodialytic conditions had to be set, including dry weight, 4 h of hemodialysis, days of the week with hemodialysis, scheduled hemodialysis hours of the day, blood flow volume, dialysis solution type (bicarbonate dialysis solution), dialysis solution flow volume, dialysis solution temperature, anticoagulant type, dialyzer type, (membrane type), meal timing, and timing of body positional changes (e.g. lifting legs and so on). Periodic body position changes were permitted only as a routine action to prevent dialysis hypotension prophylactically. Feasibility of hemodialysis under the above conditions during the observation period and the dosing period for a total of 8 weeks was confirmed.
Hemodialysis was performed with bicarbonate dialysate. The dialysate sodium concentration was 140-142 mEq/l, dialysate potassium 2 mEq/l and dialysate calcium 2.5 or 3.0 mEq/l. The duration of dialysis sessions was set to be 4 h except when infusion therapy was performed. Ultrafiltration rate was set to be constant over the course of a dialysis session. The postdialytic body weight has been governed to achieve dry weight not in every dialysis session, but at least once a week.
Blood pressure was measured every 30 min. To treat the symptoms associated with intradialytic fall of blood pressure or to prevent the further reduction of blood pressure, saline infusion was performed at first. As a rule, when SBP is less than 140 mmHg, with 20 mmHg or more reduction compared to SBP 1 h before, 100 ml (one unit) saline infusion or injection of 20 ml (one unit) of 10% NaCl is permitted.
Emergency actions other than infusion therapy were based on specific criteria. If the infusion therapy was unsuccessful, positional change (lifting the legs), reduction of ultrafiltration rate, oxygen inhalation, discontinuation of hemodialysis, and shortening of dialysis were conducted.
Evaluation of the efficacy of FK352 on dialysis hypotension
The primary assessment of FK352 efficacy was the reduction rate in the incidence of intradialytic hypotension between the placebo and the FK352 groups. Intradialytic hypotension is defined as SBP decreasing to less than 110 mmHg, with 30 mmHg or more reduction of blood pressure from the predialysis level.
An event is defined as emergency treatments against blood pressure reduction: infusion of saline or 10% NaCl, reduction of ultrafiltration, oxygen inhalation and discontinuation of hemodialysis or shortening of dialysis time. Incidence of hemodialysis sessions with intradialytic hypotension(s) and event(s) was evaluated.
In cases of excessive body weight increase due to too much food and fluid intake, however, the dialysis sessions inevitably set at an ultrafiltration rate of more than 0.3 ml/kg/min often have problems. The data were excluded from statistical analysis when patients underwent an excessive ultrafiltration rate of 0.3 ml/kg/min or more. After the exclusion of dialysis sessions with excess ultrafiltration, three patients who had less than six dialysis sessions for the data analysis were excluded.
To further analyze the efficacy of FK352 on severe intradialytic hypotension, intradialytic hypotension was defined as SBP decreasing to less than 110, 100, and 90 mmHg.
Pharmacokinetic measurement of FK352
Whole blood concentration of FK352 was analyzed before administration and at 3, 10, and 30 min and 1 and 2 h after administration of FK352 during hemodialysis. FK352 concentration was measured by liquid chromatography and mass spectrometry. Estimated plasma concentration of FK352 (C0) was calculated from the concentrations at 3 and 10 min after administration. Pharmacokinetics of normal subjects was measured in 10 healthy volunteers after informed consent was obtained from them.
Statistical analysis
For demographic and other baseline variables, Fisher's exact test, t-test or Mann-Whitney U-test were used to assess comparability between the FK352 and placebo groups. Variables that exhibited imbalance (Po0.15) between treatment groups were to be included as a covariate in secondary analysis (rank analysis of covariance) to assess the effect of the imbalance. Mann-Whitney U-test was used for group comparison (comparison between the placebo and FK352 groups) and Wilcoxon signed rank test was used for intragroup comparison (comparison between the observation and medication periods). Statistical significance level was defined as Po0.05. 
